Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday reported fourth-quarter 2025 adjusted earnings of $6.57 per share, beating the street view of $6.45.
Quarterly sales of $12.22 billion increased 7% year-over-year, beating the analyst consensus estimate of $11.95 billion. Organic revenue growth was 3%.
“Throughout the year, we effectively navigated the external environment and leveraged our PPI Business System to enable excellent operational performance. It was also a very active year for capital deployment, as we advanced our strategy and added exciting new capabilities that further strengthen our long-term competitive position,” said Marc Casper, chairman, president, and CEO of Thermo …